In partnership with
December 15, 2025
Built by a former cannabis regulator, Policy, Decoded helps operators read the policy terrain before it shifts beneath their feet.
Washington starts the morning watching for a possible Schedule 3 directive, with 280E and capital posture moving faster than the paperwork. The rest of today’s brief tracks the ripple effects, from state power and ballot fallout to hemp enforcement risk and the unglamorous plumbing that keeps markets operating.
Today’s edition is supported by Superhuman AI and 1440 Media. If you want your work in front of the same decision-makers, reply to this email to learn about sponsoring a future edition.
Latest episode of The Hybrid dropped this morning, which features Deirdra O’Gorman of Empyreal Logistics, one of the people who keeps the cash moving so this industry can function. It is available wherever you get your podcasts!
🏛️ Schedule 3 watch day
🧾 State power and ballot fallout
🎙️ The Hybrid drops today
When the music stops, you want a chair.
The Gold standard for AI news
AI keeps coming up at work, but you still don't get it?
That's exactly why 1M+ professionals working at Google, Meta, and OpenAI read Superhuman AI daily.
Here's what you get:
Daily AI news that matters for your career - Filtered from 1000s of sources so you know what affects your industry.
Step-by-step tutorials you can use immediately - Real prompts and workflows that solve actual business problems.
New AI tools tested and reviewed - We try everything to deliver tools that drive real results.
All in just 3 minutes a day
Start here — the day’s most important development, decoded for impact.
📌 What Happened: A specific rumor is hanging over Washington this morning: President Trump may issue a written directive telling federal agencies to push marijuana toward Schedule 3. Reporting says the idea came up in an Oval Office conversation that pulled in industry executives, HHS Secretary RFK Jr., CMS Administrator Dr. Oz, and Speaker Mike Johnson by phone, with Johnson pushing back and the executives pushing hard the other way. The White House is still saying there is no final decision, which is the only honest posture when nobody has seen paper with a signature. The most meaningful version of this would lean on the existing rescheduling file that is already in motion, and try to force agencies to finish it rather than letting it sit in procedural purgatory. Some of the same reporting also links this moment to talk of Medicare coverage for certain CBD treatments, which sounds simple in a meeting and gets progressively more complicated when you start asking what, exactly, gets covered, and for whom. If nothing drops today, that also tells a story, because it means that something spooked the Administration.
💡 Why It Matters: Schedule 3 would hit the P&L long before it changes what a consumer sees on store shelves. The big deal is 280E. Once cannabis is out of Schedule 1 and 2, licensed businesses finally have a path back to normal tax treatment, but only after the agencies finish the job and the rule actually takes effect. Banking can loosen at the margins too, mostly because risk teams get new language to work with, while most institutions still wait for Congress before they stop treating cannabis like a permanent compliance exception. State programs stay in charge of retail, so nobody should confuse an executive order with nationwide adult-use legality or interstate commerce. Your eyes should be on the clock, though. Does bureaucracy coordinate across departments and move fast, or do we all just turn our attention back to speculation and rumor mills? FDA, DEA, DOJ, CMS…the alphabet soups need to get in line. It is likely to get more complicated in the coming months.
🧠 THC Group Take: If - still an if - something happens today, it marks a turning point. Biden-era rescheduling always felt like a file that could be “important” and still never get the institutional energy it needed to cross the finish line. That is not a moral judgment. That is how Washington works when the work is more performative than passionate. President Trump has always operated a little more unconventionally. He likes a clean win he can claim, and he likes a storyline that fits in one sentence. Schedule 3 fits. The CMS angle fits too, because the easiest way to sell this to skeptical Republicans is to keep pointing back to medicine, veterans, seniors, and “responsible” regulation, while quietly drawing a bright line against adult-use nationalization.
Any action out of the Oval Office is still the beginning of a long walk down a federal hallway, though. Big operators and institutional investors will love the direction because 280E relief changes cash flow and makes the category easier to underwrite. A Schedule 3 posture also pulls the industry toward drug-manufacturing expectations over time, including documentation, validation, and quality systems that reward scale. That is where the small business risk, the same small businesses that states have prioritized, lives. If your state’s equity story depends on independent operators staying upright, you do not get to be passive while the federal government nudges the whole supply chain toward “pharma-ready.” Hemp is going to get dragged into this fight whether an executive order mentions it or not, because Washington keeps reaching for blunt tools and rarely bothers to separate age-gated, low-dose beverages from the sketchier intoxicants that light up headlines. Also, if CMS is going to flirt with CBD coverage, the next question writes itself: where does that CBD come from, what standards does it meet, and who is willing to defend that procurement pipeline once taxpayers are paying for it? If the White House acts, we’ll be back Tuesday to unpack it with our reaction. Need a deeper dive into all of this, or want someone to brief your team - or your board? Call us before your competitors do.
Fast-moving headlines, flagged for what matters.
Capitol Hill greeted the rescheduling chatter with a split that lines up more with incentives than ideology. Supporters framed Schedule III as overdue and practical, with taxes and research doing most of the work in their arguments. Skeptics treated it as executive branch shortcutting and warned that public health guardrails still feel thin. Nobody is pretending a directive creates federal adult-use legality, yet plenty of members are happy to take credit for “movement” without owning the messy middle. The week ahead will show who wants this outcome and who just wants the headline. (Marijuana Moment)
Cannabis equities surged on Friday after reports that the White House may push toward Schedule III. Traders treated it as a tax story first, with 280E relief sitting underneath the buying. The move also reflects a broader bet that boardrooms and lenders will relax their posture once federal classification shifts, even if compliance friction stays. Markets can price momentum in minutes, while agencies move in months. The gap between those clocks is where operators get whiplash. (Reuters)
A Wall Street Journal letter from Dr. Bertha K. Madras urges federal officials to reject Schedule III, arguing the medical evidence does not justify it. She frames rescheduling as a legitimacy boost that arrives without FDA style discipline on indications, dosing, manufacturing controls, and surveillance. The letter also casts 280E relief as a policy choice with predictable beneficiaries, warning that tax upside will outrun prevention and safeguards. This is the kind of argument that travels well in Republican circles because it wears a lab coat and keeps legalization off the table. It will be cited often if the White House tries to move quickly. (The Wall Street Journal)
Florida’s 2024 ballot fights are still producing fallout, and the money is the story. The Tampa Bay Times reports the DeSantis administration routed tens of millions in taxpayer funds into advertising and consulting tied to the abortion and adult-use cannabis amendments. The spending was framed as public information, and critics saw campaign messaging paid for with public dollars. Both measures won a majority and still failed under Florida’s 60% threshold, which gives the state a clean win and leaves opponents arguing about the means. In Florida, the executive branch treats legalization as a threat category and spends accordingly. (Tampa Bay Times)
Arkansas’s Supreme Court overturned a long-standing precedent and said lawmakers can amend or repeal voter-initiated constitutional amendments with a two-thirds vote. The case grew out of legislative changes to the state’s 2016 medical cannabis amendment, and the ruling reaches far beyond cannabis. Amendment sponsors warn it chills direct democracy by telling voters their win can be rewritten after the election. One justice agreed with the result while urging a narrower approach, which shows the court understood the blast radius. In Arkansas, ballot victory now looks like the start of a negotiation, not the end of one. (KATV)
Kentucky’s medical program is finally moving from cards to commerce, with the first dispensary sale in Beaver Dam. The launch is expected to be supply constrained, and officials have already warned inventory may sell out quickly. Kentucky’s in-state cultivation and processing requirement slowed the rollout, which means early demand is hitting a thin pipeline. More dispensaries should follow as testing and product volumes stabilize. The real measure is whether patients can find consistent, affordable inventory after the first-week excitement fades. (Spectrum News 1)
Ohio hemp retailers are watching legislation land on Gov. Mike DeWine’s desk with their futures riding on his decision. The bill would push most intoxicating hemp products out of general retail and into the licensed marijuana channel, turning today’s inventory into tomorrow’s risk. Shop owners are pitching a different model: age-gating, testing, packaging discipline, and rules that treat the category like alcohol service instead of dispensary only access. Lawmakers left a temporary lane for low-dose beverages, which keeps a narrow set of compliant operators alive while others stare at a cliff. If it is signed, the first impact will look ordinary and feel brutal. (Ohio Capital Journal)
Some North Carolina craft breweries are leaning on low-dose hemp THC drinks as beer sales soften, and some say the category keeps payroll intact. WFDD reports operators are planning around federal language that could shut the market down in late 2026, even though nobody can yet describe enforcement in plain terms. The responsible players keep describing the same playbook: age-gates, serving limits, lab work, and labels that hold up under scrutiny. Crackdowns rarely spare careful operators when politics catches fire, and that fear is already shaping production decisions. Breweries are reducing risk in quiet ways, including shorter runs and fewer bets. (WFDD)
Consumers are trying to revive a federal case accusing Cresco of labeling vape oils in ways they say skirt potency limits tied to product categories. Cresco argues classification and compliance belong with regulators, and courts should not become substitute control commissions. Plaintiffs frame it as a deception case, where labels drive legality, dosing expectations, and what a reasonable customer thinks they are buying. The larger risk is precedent, because label strategy can become deposition strategy once plaintiffs survive dismissal. If the suit moves forward, marketing teams across the industry will feel compliance sitting closer to the center of the table. (Law360)
Cannabis insurance is growing, and underwriting still feels cautious and brittle. Federal illegality and uneven state standards keep carriers conservative, and rising losses are tightening appetites in key lines. That pressure shows up in pricing, exclusions, and renewals, especially for businesses already operating on thin margins. The best run operators will still find coverage, and they will still pay for it. Everyone else gets a lesson in how fast risk becomes expensive. (The Insurer)
Debt maturities and refinancing risk are pushing operators into tougher banking conversations heading into 2026. An industry outlook argues lending is the growth lever, with better cannabis credit reporting and early efforts to make loan risk easier to carry. On compliance, it points to AI tools being used for monitoring and adverse media review so humans can spend time on judgment instead of rote work. The sorting mechanism stays simple: clean books and disciplined operations earn better terms. Operators who treated banking like a workaround are walking into higher costs. Capital gets cheaper for grown-up businesses. (Digital Journal)
A new working paper reports suicide rates fell among adults 45 and older after recreational dispensaries opened, with the effect tied to real access rather than paper legalization. The authors point to chronic pain and illness as plausible pathways, where symptom relief changes quality of life and isolation. The findings will draw methodological scrutiny, and they should. The public health conversation keeps getting flattened into slogans, and the data keeps refusing to cooperate. Policymakers who claim they are guided by health outcomes will need to wrestle with results like this. (Marijuana Moment)
Fact-based news without bias awaits. Make 1440 your choice today.
Overwhelmed by biased news? Cut through the clutter and get straight facts with your daily 1440 digest. From politics to sports, join millions who start their day informed.
From the hearing room to the comment section — we’re watching it all.
🧪 One grower profiled in MMJDaily argues that quality control starts with culture, with accountability and shared responsibility doing more work than any new piece of equipment. His facility runs a tightly scheduled hydroponic cycle with heavy automation, yet he frames the real edge as training, empowerment, and a team that feels ownership over outcomes. It is a reminder that data only matters when the people touching the process trust it and use it. (MMJDaily)
🌆 Massachusetts social consumption approval is already producing the predictable split: locals who assume it changes nothing, and visitors who want a legal place to exhale without hiding. The fight ahead is municipal, because opt-in and zoning will decide whether this becomes a handful of novelty venues or a real hospitality category. (WBZ NewsRadio)
🌾 Edibles.com’s EVP and GM Thomas Winstanley is framing the looming federal hemp language as a farm economy gut punch, warning that a “total THC” definition and a synthetic cannabinoid ban would erase much of the consumer market in 2026. That argument is aimed less at cultural anxiety and more at committee staffers who still care about rotational crops, processing jobs, and local manufacturing. When the farm-state story gains traction, it tends to travel fast because it gives lawmakers a reason to defend hemp without defending sketchy products. (Lynnwood Times)
🌍 Morocco is trying to scale legal cannabis farming in the Rif Mountains, turning a legacy illicit crop into licensed cooperatives and exportable medical and industrial supply. The legal market is still competing against the older one on price and reliability, and farmers tend to follow whoever pays consistently and buys on time. (Associated Press)